https://www.businesswire.com/news/home/20260531020433/en/Faraday-Future-Founder-and-Global-CEO-YT-Jia-Shares-Weekly-Investor-Update-Total-Sales-and-Shipments-of-EAI-Robots-Reached-69-Units-in-May-a-New-Record-Exceeding-the-Combined-Total-for-the-Months-of-March-and-April 2026-05-31T23:30:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-31T23:30:00.000Z Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Total Sales and Shipments of EAI Robots Reached 69 Units in May, a New Record, Exceeding the Combined Total for the Months of March and April FFAI https://mms.businesswire.com/media/20260531020433/en/2819657/21/0531.jpg https://www.businesswire.com/news/home/20260528004124/it 2026-05-31T22:02:00.000Z weekly 0.5 Business Wire it PressRelease 2026-05-31T22:02:00.000Z Fortegra completa l'acquisizione da parte di DB Insurance https://mms.businesswire.com/media/20260528004124/it/2817590/21/fortegra-logo-blue-v-300x129.jpg https://www.businesswire.com/news/home/20260528867319/zh-HK 2026-05-31T21:56:00.000Z weekly 0.5 Business Wire zh-HK PressRelease 2026-05-31T21:56:00.000Z Fortegra完成被DB Insurance收購的交易 https://mms.businesswire.com/media/20260528867319/zh-HK/2817590/21/fortegra-logo-blue-v-300x129.jpg https://www.businesswire.com/news/home/20260528407787/pl 2026-05-31T21:49:00.000Z weekly 0.5 Business Wire pl PressRelease 2026-05-31T21:49:00.000Z DB Insurance przejmuje Fortegra https://mms.businesswire.com/media/20260528407787/pl/2817590/21/fortegra-logo-blue-v-300x129.jpg https://www.businesswire.com/news/home/20260528727742/hu 2026-05-31T21:44:00.000Z weekly 0.5 Business Wire hu PressRelease 2026-05-31T21:44:00.000Z A DB Insurance felvásárolja a Fortegra vállalatot https://mms.businesswire.com/media/20260528727742/hu/2817590/21/fortegra-logo-blue-v-300x129.jpg https://www.businesswire.com/news/home/20260531620998/en/VRRM-Investors-Have-Opportunity-to-Join-Verra-Mobility-Corporation-Fraud-Investigation-with-the-Schall-Law-Firm 2026-05-31T21:34:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-31T21:34:00.000Z VRRM Investors Have Opportunity to Join Verra Mobility Corporation Fraud Investigation with the Schall Law Firm VRRM https://mms.businesswire.com/media/20260531620998/en/827144/21/Schall-Firm-Logo-640x360.jpg https://www.businesswire.com/news/home/20260531121860/en/PLAB-Investors-Have-Opportunity-to-Join-Photronics-Inc.-Fraud-Investigation-with-the-Schall-Law-Firm 2026-05-31T21:27:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-31T21:27:00.000Z PLAB Investors Have Opportunity to Join Photronics, Inc. Fraud Investigation with the Schall Law Firm PLAB https://mms.businesswire.com/media/20260531121860/en/827144/21/Schall-Firm-Logo-640x360.jpg https://www.businesswire.com/news/home/20260529578327/es 2026-05-31T21:14:00.000Z weekly 0.5 Business Wire es PressRelease 2026-05-31T21:14:00.000Z BeOne Medicines establece un nuevo estándar para el control a largo plazo de la leucemia linfocítica crónica (LLC) con los datos de 78 meses de BRUKINSA que se presentaron en ASCO 2026 688235,06160,ONC https://mms.businesswire.com/media/20260529578327/es/2494825/21/BGI2404_BeOne_Primary_Logo_RGB_M04_V01.jpg https://www.businesswire.com/news/home/20260529506966/zh-HK 2026-05-31T21:14:00.000Z weekly 0.5 Business Wire zh-HK PressRelease 2026-05-31T21:14:00.000Z BeOne Medicines在2026年ASCO年會上公布BRUKINSA的78個月資料，確立其在CLL長期疾病控制中的標準 688235,06160,ONC https://mms.businesswire.com/media/20260529506966/zh-HK/2494825/21/BGI2404_BeOne_Primary_Logo_RGB_M04_V01.jpg https://www.businesswire.com/news/home/20260529247109/ja 2026-05-31T21:14:00.000Z weekly 0.5 Business Wire ja PressRelease 2026-05-31T21:14:00.000Z BeOne Medicines、ASCO 2026で発表するBRUKINSAの78か月データにより、CLLにおける長期的な病勢コントロールの標準を確立 688235,06160,ONC https://mms.businesswire.com/media/20260529247109/ja/2494825/21/BGI2404_BeOne_Primary_Logo_RGB_M04_V01.jpg https://www.businesswire.com/news/home/20260529769533/de 2026-05-31T21:14:00.000Z weekly 0.5 Business Wire de PressRelease 2026-05-31T21:14:00.000Z BeOne Medicines setzt mit den 78-Monats-Daten zu BRUKINSA auf der ASCO 2026 neue Maßstäbe für die langfristige Krankheitskontrolle bei CLL 688235,06160,ONC https://mms.businesswire.com/media/20260529769533/de/2494825/21/BGI2404_BeOne_Primary_Logo_RGB_M04_V01.jpg https://www.businesswire.com/news/home/20260531595161/en/CZR-Investors-Have-the-Opportunity-to-Join-Investigation-of-Caesars-Entertainment-Inc.-with-the-Schall-Law-Firm 2026-05-31T21:05:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-31T21:05:00.000Z CZR Investors Have the Opportunity to Join Investigation of Caesars Entertainment, Inc. with the Schall Law Firm CZR https://mms.businesswire.com/media/20260531595161/en/827144/21/Schall-Firm-Logo-640x360.jpg https://www.businesswire.com/news/home/20260531630893/en/Berkshire-Hathaway-to-Acquire-Taylor-Morrison-Home-Corporation-for-%248.5-Billion 2026-05-31T20:30:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-31T20:30:00.000Z Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion TMHC,BRK.B,BRK.A https://www.businesswire.com/news/home/20260531916899/en/GAP-Investors-Have-Opportunity-to-Join-The-Gap-Inc.-Fraud-Investigation-with-the-Schall-Law-Firm 2026-05-31T20:29:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-31T20:29:00.000Z GAP Investors Have Opportunity to Join The Gap, Inc. Fraud Investigation with the Schall Law Firm GAP https://mms.businesswire.com/media/20260531916899/en/827144/21/Schall-Firm-Logo-640x360.jpg https://www.businesswire.com/news/home/20260531161413/en/Ivonescimab-with-Chemotherapy-Demonstrated-a-Statistically-Significant-Overall-Survival-Benefit-Compared-to-Tislelizumab-Plus-Chemotherapy-in-1L-Treatment-of-Patients-with-Squamous-NSCLC-in-the-HARMONi-6-Study-Conducted-by-Akeso-in-China 2026-05-31T13:06:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-31T13:06:00.000Z Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China SMMT https://mms.businesswire.com/media/20260531161413/en/2208782/21/2024-Summit-logo-RGB.jpg https://www.businesswire.com/news/home/20260531652876/en/Tempus-Unveils-the-Next-Generation-of-Lens-Expanding-its-Agentic-AI-Platform-for-Oncology-Drug-Development 2026-05-31T12:30:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-31T12:30:00.000Z Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development TEM https://mms.businesswire.com/media/20260531652876/en/566718/21/black_wordmark.jpg https://www.businesswire.com/news/home/20260531990280/en/Pfizers-BRAFTOVI-Regimen-Nearly-Doubles-Median-Progression-Free-Survival-in-Metastatic-Colorectal-Cancer 2026-05-31T12:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-31T12:00:00.000Z Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer PFE https://mms.businesswire.com/media/20260531990280/en/1045874/21/Pfizer_Logo_Color_RGB_APPROVED.jpg https://www.businesswire.com/news/home/20260531412768/en/Kelonia-Therapeutics-Presents-Updated-First-in-Human-Data-from-Phase-1-inMMyCAR-Study-of-KLN-1010-in-vivo-BCMA-CAR-T-Therapy-at-the-2026-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting 2026-05-31T12:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-31T12:00:00.000Z Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting https://mms.businesswire.com/media/20260531412768/en/2082436/21/kelonia_inline_fullcolor_rgb_12in%40300ppi_%282%29.jpg